Saturday 17 October 2026 Export KROS’s income statement to Excel — free account

Keros Therapeutics, Inc.

In the quarter to June 2026, revenue fell 99.8%, EPS fell 90.8% and free cash flow grew 32.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

10.66 0.44 −3.96%

Follow KROS

Alert me

Market cap: $220.1M
P/E: 0.0×
Fwd P/E: −1.7×
Dividend yield: —
F-score: 7/9
Altman Z: 13.47
Beneish M: 57.00
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.08

Total sells 0.52

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	1	1	1	1	1	1	—	—
Sell	—	—	—	4	—	—	—	4	—	4	—	—

Insider Ownership 8.33%

Capital & Financial Ratios $m

Market Cap 220.08

Revenue 33.18

Net Income (83.16)

Free Cash Flow (48.49)

Net Debt (257.61)

Current Ratio 21.96

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.72)

P/S ratio 6.37

P/B ratio 0.81

Past 5Y EPS Growth —

This Y EPS Growth (340.77%)

Next Y EPS Growth (12.61%)

Next Y revenue growth (93.62%)

Next 5Y EPS Growth 5.51%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 17.93%

10-year low 10-year high

P/B against its own 10 years 12.26%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2019	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	331	560	287	258
Receivables	0	3	6	2
Inventory	—	—	—	—
Other	—	—	—	—
	347	589	315	267

	2023	2024	2025	Q'26
Payables	5	5	2	2
ST’ Debt	—	—	—	—
Other	—	—	—	—
	24	27	20	12

Compound Annual Growth %

	10y	5y	3y
Sales	—	89.45%	129.84%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	2.98%	3.00%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	—	—	—	—
’25	211	18	14	0	244
’24	0	0	0	3	4
’23	—	—	0	0	0
’21	—	0	—	20	20
’19	3	3	3	3	10

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(20)	—	—	—
’25	161	(30)	3	(27)	108
’24	(45)	(40)	(30)	(46)	(161)
’23	(34)	(31)	(34)	(25)	(125)
’22	(1)	(23)	(25)	(21)	(70)
’21	(11)	(18)	(14)	(20)	(62)
’20	(8)	(10)	(11)	(8)	(37)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(4)	(21)	—	—	—
’25	161	(30)	3	(27)	106
’24	(46)	(40)	(31)	(46)	(163)
’23	(35)	(31)	(35)	(26)	(127)
’22	(2)	(23)	(25)	(22)	(71)
’21	(11)	(18)	(15)	(20)	(63)
’20	(8)	(10)	(11)	(8)	(37)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.21)	(1.45)	—	—	—
’25	3.62	(0.76)	(0.18)	(0.86)	2.30
’24	(1.21)	(1.25)	(1.41)	(1.14)	(5.00)
’23	(1.26)	(1.27)	(1.33)	(1.34)	(5.20)
’22	(1.01)	(1.13)	(0.92)	(1.09)	(4.15)
’21	(0.68)	(0.67)	(0.87)	(0.30)	(2.52)
’20	(5.11)	(0.62)	(0.60)	(0.49)	(2.93)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	—	19.10	28.50	24.38	27.02	15.33	9.12	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	—	88.80	75.99	68.29	59.96	73.00	22.55
People
People	Employees	—	—	—	23	35	60	105	136	169	78
	Revenue/emp, $m	—	—	0.00	0.43	0.00	0.34	0.00	0.00	0.02	3.13
Income, $m
Income, $m	Revenue	—	—	10	10	—	20	—	0	4	244
	Gross margin, %	—	—	0.00	100.00	0.00	100.00	0.00	100.00	100.00	100.00
	EBT	—	—	(1)	(12)	(46)	(57)	(105)	(153)	(187)	92
	EBT margin, %	—	—	(10.78)	(123.36)	0.00	(282.25)	0.00	(101,319.21)	(5,269.10)	37.65
	Net income	—	0	(1)	(12)	(45)	(59)	(105)	(153)	(187)	87
	Depreciation	—	—	0	0	0	0	1	1	1	2
Per share, $
Per share, $	Revenue	—	—	0.53	4.30	0.00	0.86	0.00	0.01	0.09	6.56
	Earnings	—	—	(0.12)	(5.30)	(2.93)	(2.52)	(4.15)	(5.20)	(5.00)	2.34
	Cash flow	—	—	0.37	(6.87)	(2.38)	(2.66)	(2.78)	(4.23)	(4.30)	2.89
	Capex	—	—	0.00	(0.12)	(0.02)	(0.04)	(0.05)	(0.08)	(0.05)	(0.04)
	Free cash flow	—	—	0.37	(6.99)	(2.40)	(2.71)	(2.82)	(4.31)	(4.35)	2.85
	Book value	—	—	(0.38)	0.21	16.88	10.42	10.99	11.28	15.27	8.14
	Shares, m	—	—	19	2	16	23	25	29	37	37
Valuation, ×
Valuation, ×	P/E	—	—	0.00	0.00	—	0.00	—	0.00	0.00	10.95
	P/S	—	—	4.99	4.99	—	54.39	—	62.72	166.94	3.11
	P/B	—	—	0.00	0.00	—	5.61	—	3.82	1.04	2.50
	EV/Sales	—	—	(0.46)	(0.46)	—	45.23	—	46.36	9.21	1.93
	EV/FCF	—	—	0.21	0.21	—	(17.97)	—	(7.39)	(0.20)	4.44
Cash, $m
Cash, $m	Operating cash flow	—	—	7	(16)	(37)	(62)	(70)	(125)	(161)	108
	Capex	—	—	0	0	0	(1)	(1)	(2)	(2)	(2)
	Free cash flow	—	—	7	(16)	(37)	(63)	(71)	(127)	(163)	106
Balance, $m
Balance, $m	Working capital	—	—	14	4	261	240	269	323	561	295
	Total debt	—	—	23	26	1	1	13	—	—	—
	Net debt	—	—	0	(7)	(266)	(230)	(279)	(331)	(560)	(287)
	Shareholders’ equity	—	—	(7)	0	262	243	277	332	572	303
Returns, %
Returns, %	ROA	—	—	(17.12)	(73.69)	(32.35)	(22.39)	(37.25)	(45.21)	(38.01)	18.24
	ROIC	—	—	0.00	0.00	0.00	(268.30)	0.00	(9,963.71)	(1,133.80)	268.69
	ROE	—	—	17.62	106.17	(37.45)	(23.27)	(40.21)	(50.19)	(41.46)	19.90

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
LXEO Lexeo Therapeutics, Inc.	$226.6M	— (loss-making)	— (loss-making)	—	n/m	+35.58% (above 0%: growing)	0.00%	0.00%	Compare
SLGL Sol-Gel Technologies Ltd.	$224.9M	— (loss-making)	— (loss-making)	−96.58% (below 0%: shrinking)	n/m	−8.76% (below 0%: shrinking)	100.00%	(704.23%)	Compare
GLSI Greenwich LifeSciences, Inc.	$224.9M	— (loss-making)	—	—	n/m	+13.14% (above 0%: growing)	0.00%	0.00%	Compare
KROS Keros Therapeutics, Inc.	$220.1M	— (loss-making)	— (loss-making)	−99.83% (below 0%: shrinking)	n/m	+32.19% (above 0%: growing)	100.00%	0.00%
PLX Protalix BioTherapeutics, Inc.	$217.5M	10.9×	10.2×	+27.07% (above 0%: growing)	+2,280.95% (above 0%: growing)	−94.09% (below 0%: shrinking)	60.99%	23.48%	Compare
CAMP CAMP4 Therapeutics Corporation	$216.5M	— (loss-making)	— (loss-making)	+18.84% (above 0%: growing)	n/m	−23.90% (below 0%: shrinking)	100.00%	(752.11%)	Compare
PYXS Pyxis Oncology, Inc.	$215.3M	— (loss-making)	— (loss-making)	—	n/m	−5.46% (below 0%: shrinking)	100.00%	0.00%	Compare
EVMN Evommune Inc.	$215.2M	— (loss-making)	— (loss-making)	—	n/m	+21.78% (above 0%: growing)	100.00%	0.00%	Compare
MGNX MacroGenics, Inc.	$214.7M	— (loss-making)	— (loss-making)	+377.97% (above 0%: growing)	n/m	+12.88% (above 0%: growing)	100.00%	(42.19%)	Compare
Median of peers	$217.0M	—	—	+22.96%	—	+3.71%	100.00%	0.00%

All 614 Biotechnology stocks →

Keros Therapeutics, Inc. (KROS) key facts

Keros Therapeutics, Inc. (KROS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, KROS traded at $10.66, a market capitalization of $220.1 million.
Return on equity was 19.9% and debt-to-equity 0.00.
Its Piotroski F-score is 7 out of 9 and its Altman Z-score is 13.47 (safe zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.